Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24608
Abstract: The introduction of bortezomib has revolutionized the treatment of multiple myeloma (MM) and significantly improved outcomes in MM patients. Similar to many other chemotherapeutic agents, there are numerous reports of bortezomib-induced cardiotoxicity. Furthermore, the FDA… read more here.
Keywords: ixazomib; induced cardiotoxicity; proteasome inhibitors; treatment ... See more keywords
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2018.12.064
Abstract: The potential of specific proteasome inhibitors to act as anti-cancer agents has attracted intensive investigations. The proteasome can be covalently inhibited by epoxyketone derivatives via a two-step reaction. Several computational approaches have been developed to… read more here.
Keywords: docking modelling; proteasome inhibitors; proteasome; covalent docking ... See more keywords
Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2022.114211
Abstract: A series of novel non-covalent peptidomimetic proteasome inhibitors possessing bulky group at the C-terminus and N-alkylation at the N-terminus were designed with the aim to increase metabolic stabilities in vivo. All the target compounds were screened… read more here.
Keywords: proteasome inhibitors; guided optimization; non covalent; ic50 ... See more keywords
New proteasome inhibitors in the treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Hematology, Transfusion and Cell Therapy"
DOI: 10.1016/j.htct.2018.07.003
Abstract: The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors… read more here.
Keywords: multiple myeloma; proteasome inhibitors; inhibitors treatment; new proteasome ... See more keywords
l-Tryptophan Schiff base cadmium(II) complexes as a new class of proteasome inhibitors and apoptosis inducers in human breast cancer cells
Sign Up to like & getrecommendations! Published in 2017 at "Inorganica Chimica Acta"
DOI: 10.1016/j.ica.2017.07.006
Abstract: Abstract Although cadmium is a widespread environmental contaminant and human carcinogen, our studies indicate an organic cadmium complex to be a potent inhibitor of proteasomal chymotrypsin-like (CT-like) activity, further capable of inducing apoptosis in a… read more here.
Keywords: human breast; proteasome inhibitors; cadmium complexes; breast cancer ... See more keywords
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2019.106271
Abstract: Multiple myeloma (MM) and mantle cell lymphoma (MCL) are blood cancers that respond to proteasome inhibitors. Three FDA-approved drugs that block the proteasome are currently on the market, bortezomib, carfilzomib, and ixazomib. While these proteasome… read more here.
Keywords: tir 199; proteasome inhibitors; syrbactin proteasome; multiple myeloma ... See more keywords
A new reporter cell line for studies with proteasome inhibitors in Trypanosoma brucei.
Sign Up to like & getrecommendations! Published in 2019 at "Molecular and biochemical parasitology"
DOI: 10.1016/j.molbiopara.2018.11.001
Abstract: A Trypanosoma brucei cell line is described that produces a visual readout of proteasome activity. The cell line contains an integrated transgene encoding an ubiquitin-green fluorescent protein (GFP) fusion polypeptide responsive to the addition of… read more here.
Keywords: trypanosoma brucei; proteasome inhibitors; cell line; line ... See more keywords
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in oncology nursing"
DOI: 10.1016/j.soncn.2017.05.005
Abstract: OBJECTIVE To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES Journal articles, research reports, state of the science papers,… read more here.
Keywords: treatment multiple; proteasome inhibitors; treatment; multiple myeloma ... See more keywords
Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00611
Abstract: With over 200 million cases and close to half a million deaths each year, malaria is a threat to global health, particularly in developing countries. Plasmodium falciparum, the parasite that causes the most severe form… read more here.
Keywords: design synthesis; macrocyclic peptides; species selective; proteasome inhibitors ... See more keywords
Fungal NRPS-PKS Hybrid Enzymes Biosynthesize New γ-Lactam Compounds, Taslactams A-D, Analogous to Actinomycete Proteasome Inhibitors.
Sign Up to like & getrecommendations! Published in 2023 at "ACS chemical biology"
DOI: 10.1021/acschembio.2c00830
Abstract: Proteasome inhibitors with γ-lactam structure, such as lactacystin and salinosporamide A, have been isolated from actinomycetes and have attracted attention as lead compounds for anticancer drugs. Previously, we identified a unique enzyme TAS1, which is… read more here.
Keywords: compounds taslactams; proteasome inhibitors; pks hybrid; fungal nrps ... See more keywords
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical science"
DOI: 10.1042/cs20190139
Abstract: Although proteasome inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines to further boost their anticancer… read more here.
Keywords: proteasome inhibitors; investigation cardiotoxicity; vitro vivo; vivo investigation ... See more keywords